Tab. Combocef
Tablet · PO · (100mg + 62.5mg) / tablet · 1 tablet
৳30.09
Tab.
Combocef
Cefpodoxime Proxetil + Clavulanic Acid
— ACI Limited
(100mg + 62.5mg) / tablet · (200mg + 125mg) / tablet
Presentations
Tab. Combocef
Tablet · PO · (200mg + 125mg) / tablet · 1 tablet
৳50.15
Dose rules
No structured dose rules are linked to this brand yet.
Dose reference
Human
For adults (Age 12 years and older): Acute bacterial exacerbation of chronic bronchitis: 1 tablet 12 hourly for 10 days Acute community acquired pneumonia: 1 tablet 12 hourly for 14 days Pharyngitis or tonsillitis: ½ tablet 12 hourly for 5 to 10 days Skin and soft tissue infections: 2 tablet 12 hourly for 7 to 14 days Urinary tract infections: ½ tablet 12 hourly for 7 days Uncomplicated gonorrhea: Single dose Acute maxillary sinusitis: 1 tablet 12 hourly for 10 days For children: Children 2 months to 12 years- 10 mg/kg/day in divided dose, every 12 hours.
Clinical notes
Applications:
- Urinary tract infection
Indication Notes:
It is indicated in the following infections - Acute bacterial exacerbation of chronic bronchitis Acute community acquired pneumonia Pharyngitis or tonsillitis Skin and soft tissue infections Urinary tract infections Uncomplicated gonorrhea Acute maxillary sinusitis
Avoid In:
N/A
Contraindication Notes:
Cefpodoxime is contraindicated in patients with known hypersensitivity to Cephalosporins.
Cefpodoxime is a third generation semi-synthetic Cephalosporin, exhibits activity against several Gram positive as well as Gram negative microorganisms. This compound is also stable in beta lactamase environment. Cefpodoxime exhibits exceptional activity against methicillin susceptible Staphylococci, Streptococcus pneumoniae, Haemophilus influenzae, Neisseria spp. and Moraxella catarrhalis.Clavulanic acid is a natural inhibitor of beta lactamase which are produced by Streptomyces clavuligerus. It binds to beta lactamase moieties and inactivates them, thus restricting the Cefpodoxime destruction.
Concomitant administration of Cefpodoxime at high doses with antacids or H2 blockers reduces peak plasma levels of Cefpodoxime.
Cefpodoxime is well tolerated. Most common gastrointestinal adverse effects are diarrhea, vomiting and abdominal pain.
US FDA pregnancy category of Cefpodoxime & Clavulanic Acid is B. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed. Cefpodoxime have been shown to be excreted in human milk. So, caution should be exercised when Cefpodoxime is administered to a nursing woman.
Cefpodoxime should be administered with caution to patients receiving concurrent treatment with diuretics.